Trial
NCT00570674
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Celgene Corporation
Condition
Squamous Cell Carcinoma of the Head and Neck
Intervention
Abraxane
Why stopped
The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-13